InvestSMART

Avecho Biotechnology Limited (ASX: AVE) - Announcements

Current share price for AVE : $0.021 0.001 (4.55%)+

ASX company news and announcements for Avecho Biotechnology Limited (AVE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Avecho Biotechnology Limited (AVE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Avecho Biotechnology Limited (AVE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Avecho Biotechnology Limited (AVE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$81 Section 708A Cleansing Statement 1 Sep 2022 9:02AM $0.012 $0.021 risen by 75%
$81 Appendix 4D and Half-year Financial Report 29 Aug 2022 9:14AM $0.013 $0.021 risen by 61.54%
$81 June 2022 Quarterly Activities Report & Appendix 4C 29 Jul 2022 8:34AM $0.013 $0.021 risen by 61.54%
$81 Security Class Reinstatement to Quotation- AVEO 14 Jul 2022 4:49PM $0.012 $0.021 risen by 75%
$81 Update on Listed Options and Federal Court Application 14 Jul 2022 4:48PM $0.012 $0.021 risen by 75%
$81 Suspension from Official Quotation - AVEO 8 Jun 2022 9:42AM $0.016 $0.021 risen by 31.25%
$81 Adoption of New Constitution 30 May 2022 4:19PM $0.019 $0.021 risen by 10.53%
$81 2022 Annual General Meeting Results 30 May 2022 4:15PM $0.019 $0.021 risen by 10.53%
$81 Chair's Address and CEO Presentation 30 May 2022 12:34PM $0.018 $0.021 risen by 16.67%
$81 Receipt of R&D Tax Incentive 3 May 2022 12:34PM $0.018 $0.021 risen by 16.67%
$81 March 2022 Quarterly Activities Report & Appendix 4C 29 Apr 2022 8:41AM $0.018 $0.021 risen by 16.67%
$81 Notice of Annual General Meeting/Proxy Form 28 Apr 2022 5:22PM $0.018 $0.021 risen by 16.67%
$81 Positive results from AVE's topical CBD pain study 29 Mar 2022 9:22AM $0.013 $0.021 risen by 61.54%
$81 Dosing begins in topical CBD pain study 1 Mar 2022 8:44AM $0.012 $0.021 risen by 75%
$81 Appendix 4G and Corporate Governance Statement 28 Feb 2022 10:05AM $0.013 $0.021 risen by 61.54%
$81 Appendix 4E and Annual Report 31 December 2021 28 Feb 2022 9:51AM $0.013 $0.021 risen by 61.54%
$81 AVE license agreement for US recreational cannabis market 2 Feb 2022 11:41AM $0.014 $0.021 risen by 50%
$81 December 2021 Quarterly Activities Report & Appendix 4C 31 Jan 2022 9:46AM $0.014 $0.021 risen by 50%
$81 Application for quotation of securities - AVE 10 Jan 2022 3:37PM $0.016 $0.021 risen by 35.48%
$81 Section 708A Cleansing Statement 10 Jan 2022 3:29PM $0.015 $0.021 risen by 40%
$81 AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis 20 Dec 2021 10:43AM $0.015 $0.021 risen by 40%
$81 Positive results from Avecho's Phase I trial of CBD soft-gel 8 Dec 2021 8:59AM $0.013 $0.021 risen by 61.54%
$81 September 2021 Quarterly Activities Report & Appendix 4C 29 Oct 2021 8:49AM $0.017 $0.021 risen by 23.53%
$81 Topical CBD pain study with Lambert Initiative approved 21 Oct 2021 8:49AM $0.018 $0.021 risen by 16.67%
$81 Dosing begins in Phase I PK trial testing CBD soft-gel 4 Oct 2021 9:22AM $0.018 $0.021 risen by 16.67%

151 - 175 of 316 results

Page 7 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.